Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Multiple Myeloma through trial conditions or approval indications mapped to it or to one of its descendant entities.
6 drugs · 36 active trials
25 drugs · 1,009 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Selumetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-03 |
| Temozolomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 15, 2019 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-08 |
| Uprosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 30, 2013 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-10 |
| Vatalanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-09 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
| Carboplatin | Phase 1 | Phase 1 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 29, 2006 |
| Hydroxychloroquine | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-06 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-11 |
| Idelalisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-06 |
| Navtemadlin | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 27, 2012 |
| Ridaforolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-04 |
| Abiraterone | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Alpelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2014 |
| Bicalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Blinatumomab | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 27, 2017 |
| Bone Marrow Transplantation | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-08 |
| Cabazitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Capecitabine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Darolutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Dovitinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-02 |
| Duvelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 18, 2021 |
| Enasidenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Entrectinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Enzalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Ganetespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-01 |
| HDAC Inhibitor REC-2282 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 4, 2010 |
| Imatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Imatinib Mesylate | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-08 |
| Lenvatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Lorlatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Mcl-1 Inhibitor MIK665 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 23, 2021 |
| MUC1-targeted Peptide GO-203-2C | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | — |
| Neratinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Pirtobrutinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 30, 2021 |
| Ponatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Regorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Retaspimycin Hydrochloride | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-06 |
| Tremelimumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 13, 2016 |
| PCV Regimen | Phase not stated | N/A | 0 | 0 | 0 | 1 | 0 | — | — | 2013-02 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.